CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
75.90
+0.04 (0.05%)
Sep 2, 2026, 10:07 AM EDT - Market open

CG Oncology Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $91.08. The average 1-year stock price forecast is 20.00% higher than the current stock price, while the lowest is $79 (+4.08%) and the highest is $108 (+42.29%).

Price Target: $91.08 (+20.00%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$79$91.08$90$108
Change+4.08%+20.00%+18.58%+42.29%

Analyst Ratings

The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy111111111010
Buy444444
Hold001111
Sell000000
Strong Sell000000
Total151516161515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Reiterates
$90
BuyReiterates$90+18.58%Aug 20, 2026
Morgan Stanley
Morgan Stanley
Buy
Reiterates
$93
BuyReiterates$93+22.53%Aug 17, 2026
Truist Financial
Truist Financial
Buy
Maintains
$85
BuyMaintains$85+11.99%Aug 11, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$108
BuyMaintains$108+42.29%Aug 7, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterates
$105
BuyReiterates$105+38.34%Aug 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.47M
from 4.04M
Increased by 10.64%
Revenue Next Year
83.52M
from 4.47M
Increased by 1,768.48%
EPS This Year
-3.20
from -2.08
EPS Next Year
-3.02
from -3.20
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
10.36M191.00K204.00K1.14M4.04M4.47M
Revenue Growth
--98.16%6.81%458.33%254.70%10.64%
Operating Income
-12.61M-35.25M-55.45M-114.67M-190.77M-319.86M
Net Income
-12.84M-35.44M-48.61M-88.04M-161.00M-292.87M
EPS
-----2.08-3.20
Free Cash Flow
--16.95M-28.07M-59.08M-87.62M-281.58M
No. Analysts
-----13
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High18.3M
Avg4.5M
Low2.2M

Revenue Growth

Revenue Growth202620272028
High
351.7%
Avg
10.6%
Low
-45.5%

EPS Forecast

EPS202620272028
High-2.79
Avg-3.20
Low-3.60

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-